Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2024-08-01 Board/Management Inform…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Zgłoszenie kandydatów na Członka Rady Nadzorczej PolTREG S.A. - Content (PL)
Board/Management Information Classification · 95% confidence The document text, written in Polish, discusses the receipt of nominations for candidates (Hubert Staszewski and Paweł Mańdok) for the Supervisory Board (Rada Nadzorcza) of the company (PolTREG S.A.) ahead of an Extraordinary General Meeting (Nadzyczajne Walne Zgromadzenie). It explicitly mentions that the professional resumes ('Życiorysy zawodowe') of the candidates are attached as appendices to the report. This content directly relates to the composition of the board of directors/supervisory board and the process leading up to a shareholder meeting where such appointments are confirmed. This aligns best with the 'Board/Management Information' (MANG) category, which covers announcements of changes in the board of directors or senior management. Although it relates to an upcoming AGM, the core subject is the nomination of board members, not the AGM materials themselves (AGM-R) or proxy solicitation (PSI).
2024-08-01 Polish
Warunkowa autoryzacja Europejskiej Agencji Leków badania klinicznego fazy II w projekcie PreTreg (cukrzyca przedobjawowa typu 1) - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is very short (616 characters) and announces that the Management Board of PolTREG S.A. received conditional authorization from the European Medicines Agency (EMA) for a Phase II clinical trial (PreTreg project for pre-symptomatic Type 1 diabetes). It explicitly states that the final decision will follow the fulfillment of certain conditions and that the Issuer will inform about the final decision in a separate current report (raport bieżący ESPI). Because this is a specific announcement regarding regulatory/clinical trial progress, and it is not a full report (like AR or IR), it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update that doesn't match the other specialized codes (like LTR for legal proceedings or CAP for financing). Given the nature of the announcement (regulatory/clinical trial update), RNS is the most appropriate fallback.
2024-07-23 Polish
Zaktualizowane ogłoszenie o zwołaniu Nadzwyczajnego Walnego Zgromadzenia
AGM Information Classification · 98% confidence The document is titled "OGŁOSZENIE O ZWOŁANIU NADZWYCZAJNEGO WALNEGO ZGROMADZENIA" (Announcement on Convening an Extraordinary General Meeting) and details the date, time, location, and agenda for a shareholder meeting on August 8, 2024. It extensively covers procedures for participation, voting rights, proxy appointments, and the record date ('Dzień Rejestracji'). This content is characteristic of materials related to convening a general meeting, which falls under the scope of AGM Information (AGM-R) or Proxy Solicitation & Information Statement (PSI). Since the primary focus is the formal convening notice and the rules governing the meeting itself, AGM-R is the most precise fit, as it covers 'Presentations and materials shared during the Annual General Meeting (AGM)'—and by extension, the notice to convene it. It is not a DEF 14A (Remuneration) or a DVA (Voting Results). Given the explicit mention of convening the meeting, AGM-R is selected.
2024-07-19 Polish
Zmiana miejsca odbycia Nadzwyczajnego Walnego Zgromadzenia Akcjonariuszy PolTREG S.A. - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is a formal announcement from the Management Board (Zarząd) of PolTREG S.A. regarding a change in the venue for the Extraordinary General Meeting of Shareholders (Nadzwyczajne Walne Zgromadzenie Akcjonariuszy) scheduled for August 8, 2024. This is a specific notification related to the logistics of a shareholder meeting, referencing a prior announcement. Since it is an announcement about the logistics of a meeting rather than the meeting materials themselves (AGM-R) or the voting results (DVA), it falls under general regulatory announcements. Given the specific nature of announcing meeting logistics changes, and the lack of a more precise category for meeting logistics updates, it is best classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure to the market about an upcoming corporate event.
2024-07-19 Polish
Projekty uchwał na NWZA
AGM Information Classification · 98% confidence The document text explicitly mentions 'PROJEKTY UCHWAŁ na Nadzwyczajne Walne Zgromadzenie' (Draft Resolutions for the Extraordinary General Meeting) dated August 8, 2024. It details specific resolutions ('UCHWAŁA Nr 1', 'UCHWAŁA Nr 2', 'UCHWAŁA Nr 3') concerning the election of the meeting chairman, approval of the agenda, and the appointment of a Supervisory Board member. These materials are directly related to the proceedings and proposals for a General Meeting. Since the document contains the draft resolutions intended for voting at the meeting, it aligns best with the 'AGM Information' category, which covers presentations and materials shared during the Annual General Meeting (AGM) or, by extension, Extraordinary General Meetings (EGM). Although it is a draft, it is core AGM material.
2024-07-12 Polish
Ogłoszenie o NWZA
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled 'OGŁOSZENIE O ZWOŁANIU NADZWYCZAJNEGO WALNEGO ZGROMADZENIA' (Announcement on Convening an Extraordinary General Meeting) and details the date, time, location, and agenda for a shareholder meeting. It extensively covers procedures for participation, voting rights, proxy appointments, and the record date ('Dzień Rejestracji'). This content is characteristic of a formal notice sent to shareholders to inform them about an upcoming meeting and solicit their participation/votes. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. Although it is a notice about a meeting, it contains the detailed information typically found in proxy materials, rather than just being a brief announcement of report publication (RPA).
2024-07-12 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.